1-3 of 3
Tim Hughes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of "Log Reduction from Median Pretherapeutic Value" vs Ratio BCR-ABL/ABL to Express the Therapeutic Response in CML Patients.

Peter Paschka, MD, Susan Branford, Christian Lorentz, MD, Rüdiger Hehlmann, MD, Tim Hughes, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2004) 104 (11): 1013.
https://doi.org/10.1182/blood.V104.11.1013.1013
Published: 2004
Journal Articles

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes
Journal: Blood
Blood (2004) 104 (9): 2926–2932.
https://doi.org/10.1182/blood-2004-03-1134
Published: 2004
Journal Articles

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Clinical Trials & Observations
Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, Tim Hughes
Journal: Blood
Blood (2003) 102 (1): 276–283.
https://doi.org/10.1182/blood-2002-09-2896
Published: 2003